Clinical Trial Update: To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids [Phase 1]

View source ↗

Summary

Phase 1 study assessing the pharmacokinetics, safety, and tolerability of once-daily abediterol in asthma patients on inhaled corticosteroids.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Abediterol (abediterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 1 | Status: COMPLETED